26 Result(s)

Article

Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome

Allogeneic hematopoietic stem cell transplant (AHSCT) outcomes data of older AML/myelodysplastic syndrome (MDS) patients are limited. We retrospectively evaluated consecutive patients ⩾60 years old with AML/MD...

D Modi, A Deol, S Kim, L Ayash, A Alavi, M Ventimiglia… in Bone Marrow Transplantation (2017)

Article

Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort

Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However, these report...

Z Gul, E Van Meter, M Abidi, I Ditah, M Abdul-Hussein… in Bone Marrow Transplantation (2015)

Article

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT

We performed a retrospective analysis of the outcome of 197 consecutive unrelated donor transplant recipients who received GVHD prophylaxis either TM regimen (tacrolimus and mycophenolate) (121 patients) or TM...

V Ratanatharathorn, A Deol, L Ayash, S Cronin, D Bhutani… in Bone Marrow Transplantation (2015)

Article

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML

We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 (24%) had failed two or m...

A Deol, J Abrams, A Masood, Z Al-Kadhimi, M H Abidi, L Ayash… in Bone Marrow Transplantation (2013)

Article

Large pericardial effusion as a complication in adults undergoing SCT

Large pericardial effusion (LPE) leading to cardiac tamponade is a rare complication described in patients undergoing SCT. This complication is considered to be a manifestation of chronic GVHD; however its pat...

M Norkin, V Ratanatharathorn, L Ayash, M H Abidi… in Bone Marrow Transplantation (2011)

Article

Clinical feasibility of TBI with helical tomotherapy

Our purpose was to present the clinical feasibility of TBI with helical tomotherapy (HT) in four patients with AML. Treatment planning, delivery, dose verification and summation, toxicity and patient outcomes ...

J A Peñagarícano, M Chao, F Van Rhee, E G Moros, P M Corry… in Bone Marrow Transplantation (2011)

Article

Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia

We retrospectively compared clinical outcomes in 1593 T-replete unrelated donor (URD) marrow transplant recipients with AML, MDS and CML who received myeloablative conditioning regimens of either BU and CY (Bu...

J P Uberti, M-A Agovi, S Tarima, M Haagenson, S Gandham… in Bone Marrow Transplantation (2011)

Article

Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD

S Mellon-Reppen, V Ratanatharathorn, S Cronin, J P Uberti in Bone Marrow Transplantation (2010)

Article

Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Chronic graft-versus-host disease (cGVHD) is the most common late complication of allogeneic hematopoietic cell transplantation (HCT) causing significant morbidity and mortality. The kidneys are not considered...

P Reddy, K Johnson, J P Uberti, C Reynolds, S Silver… in Bone Marrow Transplantation (2006)

Article

Do negative or positive emotions differentially impact mortality after adult stem cell transplant?

Multiple diverse biomedical variables have been shown to affect outcome after hematopoietic stem cell transplantation (HSCT). Whether psychosocial variables should be added to the list is controversial. Some e...

F Hoodin, J P Uberti, T J Lynch, P Steele… in Bone Marrow Transplantation (2006)

Article

Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes

We report long-term outcomes for allogeneic peripheral blood stem cell (PBSC) recipients, evaluating cumulative incidence (CI) of acute and chronic graft-versus-host disease (GVHD), after use of tacrolimus wit...

J P Uberti, L Ayash, T Braun, C Reynolds, S Silver… in Bone Marrow Transplantation (2004)

Article

West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem cell transplantation

We describe here a patient who died of progressive CNS deterioration following allogeneic stem cell transplant with West Nile virus as the sole pathogen on the cerebrospinal fluid and brain tissue analysis. A ...

P Reddy, R Davenport, V Ratanatharathorn, C Reynolds… in Bone Marrow Transplantation (2004)

Article

Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients

Tacrolimus is an immunosuppressant commonly used in the prevention of graft-versus-host disease (GVHD) following allogeneic HCT. Unfortunately, the use of tacrolimus is associated with variable immunosuppressi...

P Jacobson, J Ng, V Ratanatharathorn, J Uberti, RC Brundage in Bone Marrow Transplantation (2001)

Article

Chronic graft-versus-host disease: clinical manifestation and therapy

Chronic graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in long-term survivors of allogeneic stem cell transplantation. The immunopathogenesis of chronic GVHD is, in part, TH-2 med...

V Ratanatharathorn, L Ayash, HM Lazarus, J Fu, JP Uberti in Bone Marrow Transplantation (2001)

Article

Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review

Testicular cancer patients refractory or in relapse after primary chemotherapy have ⩽25% 5-year progression-free survival with salvage. To improve prognosis, patients entered a phase I/II tandem dose-escalatio...

LJ Ayash, M Clarke, SM Silver, T Braun, J Uberti… in Bone Marrow Transplantation (2001)

Article

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma

This study compares the probability of disease progression, progression-free survival, and overall survival between patients undergoing an allogeneic or autologous transplant for multiple myeloma using an iden...

C Reynolds, V Ratanatharathorn, P Adams, T Braun, S Silver… in Bone Marrow Transplantation (2001)

Article

Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation

This report describes two patients with germ cell tumors who underwent tandem autologous peripheral stem cell transplants. The chemotherapy consisted of high-dose carboplatin and etoposide. Both patients devel...

S Cronin, JP Uberti, LJ Ayash, C Raith, V Ratanatharathorn in Bone Marrow Transplantation (2000)

Article

Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation

Currently, limited data exist on the role of tacrolimus (FK506) in pediatric allogeneic marrow transplantation. Forty-one patients who received tacrolimus as prophylaxis were reviewed, with a median age of 9 y...

G Yanik, JE Levine, V Ratanatharathorn, R Dunn, J Ferrara… in Bone Marrow Transplantation (2000)